Ligand Pharmaceuticals announces completion of enrollment of the Company’s Phase 1 clinical trial of its internal Captisol-enabled, or CE, Iohexol program. The CE-Iohexol program is designed to develop a Captisol-enabled, next-generation contrast agent for diagnostic imaging with a reduced risk of renal toxicity. Ligand also provides below a summary of the findings of a survey of clinicians on radiocontrast agent selection and use.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.